The myths that drive therapeutic inertia in multiple sclerosis: a cost-effectiveness analysis of high-efficacy drugs in Brazil

Arq Neuropsiquiatr. 2024 Jan;82(1):1-2. doi: 10.1055/s-0044-1779036. Epub 2024 Feb 5.
No abstract available

MeSH terms

  • Brazil
  • Cost-Effectiveness Analysis
  • Glatiramer Acetate / therapeutic use
  • Humans
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy

Substances

  • Glatiramer Acetate